Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics

Simple Summary Small-cell lung cancer (SCLC) is an aggressive type of lung cancer, often linked to a poor prognosis for the majority of patients. Platinum–etoposide-based chemotherapy, combined with immunotherapy, constitutes the standard treatment for patients with small-cell lung cancer (SCLC). Nonetheless, SCLC often recurs and develops resistance to treatment. The development of targeted treatment options for patients with SCLC has presented challenges; however, several emerging therapies demonstrate potential efficacy. Recent progress in SCLC research has uncovered essential insights into the biological traits of the disease, which could facilitate the discovery of biomarkers. Additionally, evaluating novel therapies will be crucial for enhancing treatment outcomes for patients with SCLC.

• Publication year

  2025

• Venue

  Cancers

• Publication date

  2025-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/cancers17020255PMID 39858036PMCID 11764476
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract 3191: Chk1/2 inhibition enhances response to lurbinectedin treatment in small cell lung cancer

  2024cited by this paper
• Small cells – big issues: biological implications and preclinical advancements in small cell lung cancer

  2024cited by this paper
• Small Cell Lung Cancer—An Update on Chemotherapy Resistance

  2024cited by this paper
• A phase I/Ib study of the aurora kinase A inhibitor alisertib in combination with osimertinib in advanced osimertinib-resistant EGFR-mutated lung cancer.

  2024cited by this paper
• P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study

  2024cited by this paper
• Comprehensive Review on the Effect of Stem Cells in Cancer Progression

  2024cited by this paper
• 195MO Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity

  2024cited by this paper
• PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

  2024cited by this paper
• Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer

  2024cited by this paper
• Small Cell Lung Cancer: New Hope, New Challenges

  2024cited by this paper
• Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1

  2023cited by this paper
• Differences between Advanced Large Cell Neuroendocrine Carcinoma and Advanced Small Cell Lung Cancer: A Propensity Score Matching Analysis

  2023cited by this paper
• Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target

  2023cited by this paper
• Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

  2023cited by this paper
• HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy

  2023cited by this paper
• Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

  2023cited by this paper
• Small Cell Lung Carcinoma: Current Diagnosis, Biomarkers, and Treatment Options with Future Perspectives

  2023cited by this paper
• Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer

  2023cited by this paper
• A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

  2023cited by this paper
• Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.

  2023cited by this paper
• Meta‐analysis of PD‐(L)1 inhibitor plus chemotherapy versus chemotherapy as first‐line treatment in extensive‐stage small‐cell lung cancer

  2023cited by this paper
• KDM6A epigenetically regulates subtype plasticity in small cell lung cancer

  2023cited by this paper
• Abstract CT218: A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas

  2023cited by this paper
• Efficacy and safety of firwst-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.

  2023cited by this paper
• Small Cell Lung Cancer in Light/Never Smokers - A Role for Molecular Testing?

  2023cited by this paper
• A multiplexed in vivo approach to identify driver genes in small cell lung cancer

  2022cited by this paper
• Small Cell Lung Cancer: Subtypes and Therapeutic Implications.

  2022cited by this paper
• Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.

  2022cited by this paper
• Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.

  2022cited by this paper
• Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

  2022cited by this paper
• DLL3 regulates Notch signaling in small cell lung cancer

  2022cited by this paper
• Pulmonary Neuroendocrine Cells and Small Cell Lung Carcinoma: Immunohistochemical Study Focusing on Mechanisms of Neuroendocrine Differentiation

  2022cited by this paper
• Small Cell Lung Cancer: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection.

  2022cited by this paper
• PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.

  2022cited by this paper
• Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

  2022cited by this paper
• Yeast β-glucan Increases Etoposide Sensitivity in Lung Cancer Cell Line A549 by Suppressing Nuclear Factor Erythroid 2-Related Factor 2 via the Noncanonical Nuclear Factor Kappa B Pathway

  2022cited by this paper
• Signal pathways and precision therapy of small-cell lung cancer

  2022cited by this paper
• Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset

  2022cited by this paper
• Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

  2021cited by this paper
• Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial

  2021cited by this paper
• Lurbinectedin in the treatment of relapsed small cell lung cancer.

  2021cited by this paper
• Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

  2021cited by this paper
• Small-cell lung cancer in never-smokers

  2021cited by this paper
• Pathology and Classification of SCLC

  2021cited by this paper
• A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

  2021cited by this paper
• Molecular profiles of small cell lung cancer subtypes: therapeutic implications

  2021cited by this paper
• Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor

  2021cited by this paper
• YAP drives fate conversion and chemoresistance of small cell lung cancer

  2021cited by this paper
• PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses

  2021cited by this paper
• Therapeutic Targeting of Cancer Stem Cells in Lung, Head and Neck, and Bladder Cancers

  2021cited by this paper
• Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

  2021cited by this paper
• Rlf-Mycl gene fusion drives tumorigenesis and metastasis in a mouse model of small cell lung cancer.

  2021cited by this paper
• Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

  2021cited by this paper
• Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.

  2021cited by this paper
• Overcoming chemotherapy resistance in Small Cell Lung Cancer.

  2021cited by this paper
• An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer

  2021cited by this paper
• Impacts of Epigenetic Processes on the Health and Productivity of Livestock

  2021cited by this paper
• Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

  2021cited by this paper
• Small-cell lung cancer

  2021cited by this paper
• Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies

  2021cited by this paper
• Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study.

  2021cited by this paper
• YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to Therapy

  2020cited by this paper
• New insights into small‐cell lung cancer development and therapy

  2020cited by this paper
• Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.

  2020cited by this paper
• A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity

  2020cited by this paper
• CLINICAL AND GENOMIC CHARACTERISTICS OF SMALL CELL LUNG CANCER IN NEVER-SMOKERS: RESULTS FROM A RETROSPECTIVE MULTICENTER COHORT STUDY.

  2020cited by this paper
• YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed Phenotype.

  2020cited by this paper
• Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation

  2020cited by this paper
• Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.

  2020cited by this paper
• Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization.

  2020cited by this paper
• MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity

  2020cited by this paper
• Current development of CBP/p300 inhibitors in the last decade.

  2020cited by this paper
• Bronchioalveolar stem cells derived from mouse-induced pluripotent stem cells promote airway epithelium regeneration

  2020cited by this paper
• FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer

  2020cited by this paper
• Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation

  2020cited by this paper
• NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.

  2020cited by this paper
• PTCH1 regulates anchorage-independent growth and bone invasion of non-small cell lung cancer cells.

  2020cited by this paper
• Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

  2020cited by this paper
• Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor

  2020cited by this paper
• Cancer stem cells and their unique role in metastatic spread.

  2020cited by this paper
• PARP and PARG inhibitors in cancer treatment.

  2020cited by this paper
• A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer

  2020cited by this paper
• Developmental changes in the accessible chromatin, transcriptome and Ascl1-binding correlate with the loss in Müller Glial regenerative potential

  2020cited by this paper
• A Semiquantitative Scoring System May Allow Biopsy Diagnosis of Pulmonary Large Cell Neuroendocrine Carcinoma.

  2019cited by this paper
• Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells

  2019cited by this paper
• Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data

  2019cited by this paper
• Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells

  2019cited by this paper
• Tuft cells: From the mucosa to the thymus.

  2019cited by this paper
• A novel mutation panel for predicting etoposide resistance in small-cell lung cancer

  2019cited by this paper
• Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.

  2019cited by this paper
• An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

  2019cited by this paper
• EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

  2019cited by this paper
• Tobacco exposure and somatic mutations in normal human bronchial epithelium

  2019cited by this paper
• Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.

  2019cited by this paper
• DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail

  2019cited by this paper
• PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?

  2019cited by this paper
• MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer

  2019cited by this paper
• Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases.

  2019cited by this paper
• Poly(ADP-ribose)-dependent chromatin unfolding facilitates the association of DNA-binding proteins with DNA at sites of damage

  2019cited by this paper
• Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.

  2019cited by this paper

• Epigenetic remodeling and apoptotic activation by Chidamide suppress small cell lung cancer in molecularly distinct subtypes

  2026cites this paper
• Continuing Immunotherapy Beyond Progression Prolongs the Survival of Patients With Extensive‐Stage Small‐Cell Lung Cancer: A Multicenter Retrospective Analysis

  2026cites this paper
• Anticancer effects and mechanisms of Pulsatilla chinensis, Bupleurum chinense and Polyporus umbellatus on human lung carcinoma and hepatoma cells

  2025cites this paper
• Competing risk model for prognosis of small cell neuroendocrine lung carcinoma based on SEER database

  2025cites this paper
• Case report: Anlotinib plus oral etoposide: a potential salvage therapy based on insights from EGFR-TKI-resistant SCLC transformation PDX and clinical settings

  2025cites this paper
• Case Report: Evolution and targeted therapy of an EGFR-mutant large-cell neuroendocrine carcinoma

  2025influential citation
• Long Noncoding RNA Lnc-MTPAP-1 Overexpressed by Particulate Matter Suppresses Apoptosis in Non-Small Cell Lung Cancer (NSCLC) Cells

  2025cites this paper
• Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions

  2025influential citation
• Immunotherapy for Limited-Stage Small Cell Lung Cancer: Innovative Treatments and Future Perspectives

  2025cites this paper
• ALK-Targeted Therapy: Resistance Mechanisms and Emerging Precision Strategies

  2025cites this paper
• Repurposing Clinical TKIs as CHK1 Inhibitors for SCLC: A Structure-Based Evaluation

  2025cites this paper
• Theoretical Insight to Explore Ti3C2@ZnO Composites towards Sensing of Isoprene for Diagnosis of Lung Cancer

  2025cites this paper
• Case Report: Ivonescimab in EGFR-mutant lung cancer with baseline malignant pleural effusion and acquired complex resistance

  2025cites this paper
• A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)

  2025cites this paper
• Improved somatic mutation profiling in small-cell lung cancer using RNA-sequencing and the T2T-CHM13 genome reference

  2025cites this paper
• Case Report: SMARCA4-deficient NSCLC with brain metastasis harboring co-mutations in chromatin remodeling and DNA damage repair pathways

  2025cites this paper
• Role of Yin Yang 1 (YY1) on microenvironment, signaling pathways, and epigenetics in lung cancer.

  2025cites this paper